Equillium’s immuno-inflammatory drug wins FDA’s orphan drug status; Vanda sues FDA for mandating lengthy dog study

? San Diego-based Equillium has nabbed an orphan drug designation for EQ001 on the verge of beginning a Phase Ib/II for the immuno-inflammatory drug. Also known as itolizumab, the drug was in-licensed from India’s Biocon, which sells it in the country as a psoriasis treatment. Equillium $EQ, however, is focusing its US clinical work on the prevention and treatment of acute graft-versus-host disease — a strategy that has allowed it to skip financing rounds and jump str

Click to view original post

Advertise With Us